key: cord-0897288-ztyme64i
authors: Bansal, Naveen; Raturi, Manish
title: Vaccination COVID-19 chez les donneurs de sang indiens: évaluer l'impact sur la période de report
date: 2021-04-12
journal: Transfus Clin Biol
DOI: 10.1016/j.tracli.2021.04.002
sha: 90ca8ddc5d92f714bb214e8d2fca977efdb1d710
doc_id: 897288
cord_uid: ztyme64i

The only efficacious way to provide people with herd immunity against the novel corona virus [nCoV] is to administer an appropriate vaccine and help check the current pandemic. With the genetic sequence data of the nCoV already available since January 10, 2020, leading pharmaceutical companies, world over, in turn, have started working on the clinical trials to produce vaccines against this nCoV. In fact, many vaccines under the Phase III trial have claimed to demonstrate their efficacy as high as 95% against nCoV. In India as of now, two vaccines have been licensed namely, Covishield (Live vaccine, Oxford AstraZeneca, United Kingdom) and Covaxin (inactivated vaccine, Bharat Biotech, India). Although, most of the countries offer no deferral period for the donors who have been administered an inactivated vaccine against this nCoV. However, the national blood transfusion council of India has recently recommended a donor deferral period of 28 days from the last dose of vaccination. This could essentially lead to a massive loss of eligible blood donors and jeopardise the already disrupted blood supply management due to the COVID-19 outbreak. The authors herein, propose a thorough redefining of this deferral period post-vaccination amongst the Indian blood donors.

The only efficacious way to provide people with herd immunity against the novel corona virus [nCoV] is to administer an appropriate vaccine and help check the current pandemic. With the genetic sequence data of the nCoV already available since January 10, 2020, leading pharmaceutical companies, world over, in turn, have started working on the clinical trials to produce vaccines against this nCoV. In fact, many vaccines under the Phase III trial have claimed to demonstrate their efficacy as high as 95% against nCoV. In India as of now, two vaccines have been licensed namely, Covishield (Live vaccine, Oxford AstraZeneca, United Kingdom) and Covaxin (inactivated vaccine, Bharat Biotech, India). Although, most of the countries offer no deferral period for the donors who have been administered an inactivated vaccine against this nCoV. However, the national blood transfusion council of India has recently recommended a donor deferral period of 28 days from the last dose of vaccination. This could essentially lead to a massive loss of eligible blood donors and jeopardise the already disrupted blood supply management due to the COVID-19 outbreak. The authors herein, propose a thorough redefining of this deferral period postvaccination amongst the Indian blood donors. with immunity against SARS-CoV-2 is to discover and produce an appropriate vaccine for developing herd immunity to end the current pandemic of COVID-19. With the genetic sequence data of the nCoV already available since January 10, 2020, leading pharmaceutical companies, the world over, in turn, have started working on the clinical trials to produce vaccines against this nCoV. In fact, many vaccines under the Phase III trial have claimed to demonstrate their efficacy as high as 95% against nCoV. In India as of now, two vaccines have been licensed namely, Covishield (Oxford AstraZeneca, United Kingdom) and

Covaxin (Bharat Biotech, India). The major difference between these two vaccines is that the Covishield is a live vaccine while Covaxin is an inactivated vaccine. The ultimate aim of blood transfusion services

[BTS] is to provide blood that is safe for transfusion. In fact, the pre-donation donor screening is the first and the most important step to ensure the safety of the blood supply. This involves the use of a donor questionnaire and a mini-physical examination to ensure both donors as well as the recipient's safety.

Blood from a recently vaccinated donor with a live vaccine may contain an infective agent which can theoretically be transmitted through blood transfusion especially in immunocompromised recipients. 

The blood supply management amid the COVID-19 outbreak

World Health Organization. Interim Guidance on COVID-19

The active role of a blood center in outpacing the transfusion transmission of COVID-19

COVID-19 transmission and blood transfusion: A case report